A publicly traded Oncology company with 3 technology platforms and limited resources was in need of narrowing their indication focus. Their next generation cancer vaccine technology demonstrated early proof of principle in 14 unique tumor types and retained Kineticos to conduct an indication prioritization exercise. The primary objective of the engagement was to objectively select 2-5 scientifically promising tumor types that also presented commercial opportunity and aligned with the firm’s corporate strategy.
For the full case study including example deliverables, click here: Indication Prioritization
Subscribe to the Kineticos Research Institute to receive weekly emails containing insightful content.